Dr. Roberto Andrade, MD

Dr. Andrade practices at Gerid Hiv in Houston, Texas.

Dr. Andrade's NPI, 1508946922, was assigned on October 17, 2006. Dr. Andrade graduated from McGovern Medical School in 2003. Dr. Andrade holds Texas license L7302.

Dr. Andrade's primary practice is Gerid Hiv, at 19255 Park Row Dr, Houston, TX 77084. The practice phone is (713) 965-6444.

Dr. Andrade's primary practice is Gerid Hiv in Houston, Texas. Dr. Andrade is also affiliated with Houston Methodist West Hospital. The medical group on file is GerID Medical Consultants. Dmand AI also links Dr. Andrade to 1 more physician office, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Andrade practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Andrade's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Andrade is board certified in infectious disease by the American Board of Internal Medicine. Dr. Andrade is licensed in Texas.

Dmand AI lists acute skin infection, arthritis, chronic anemia, chronic diabetes, chronic hypertension, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and coronary artery disease among the conditions Dr. Andrade treats.

CMS data shows 8,494 Medicare services from Dr. Andrade across 12 procedure codes in 2024, for 390 Medicare patients. Medicare paid $252,019 for them.

CMS counts 390 Medicare patients who saw Dr. Andrade in 2024. The largest group is 65 to 74, with 146 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 3.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Andrade's median patient age at 67, with 48% women.

In 2024, Dr. Andrade wrote 999 Medicare Part D claims for 200 patients. 78% of them were for generic drugs. CMS names the drug for 830 of them, across 27 drugs with 11 or more claims each, at $681,761 in total drug cost. In 2023, CMS named 709 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Andrade for performance year 2024, reported individually. Dr. Andrade accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Andrade, published from 2009 to 2016. 2013 was the busiest year, with 2. The most frequent topics are HIV Infections, Anti-HIV Agents and Medication Adherence. Dr. Andrade's most frequent co-authors are Mayar Al Mohajer, MD, Elizabeth Y. Chiao, MD and Andrew R. Dinardo, MD.

CMS Open Payments shows 383 general payments to Dr. Andrade from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Gilead Sciences, Inc. paid the most, $1,398.

Dr. Andrade graduated from McGovern Medical School in 2003.

Dr. Andrade is in network with 22 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.